Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
19 Apr 24
PRE 14C
Preliminary information
19 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
25-NSE
Exchange delisting
21 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
26 Feb 24
10-Q
2024 Q3
Quarterly report
12 Feb 24
DEFA14A
Additional proxy soliciting materials
17 Jan 24
DEF 14A
Definitive proxy
17 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jan 24
8-K
Important Update on Listing Status and Strategic Direction
3 Jan 24
8-K
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
13 Dec 23
PRE 14A
Preliminary proxy
7 Dec 23
8-K
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
21 Nov 23
8-K
Regulation FD Disclosure
14 Nov 23
8-K
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
14 Nov 23
10-Q
2024 Q2
Quarterly report
13 Nov 23
8-K
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
13 Nov 23
8-K
Other Events
12 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Oct 23
8-K
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
14 Sep 23
8-K
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
13 Sep 23
424B8
Prospectus unintentially filed late
11 Sep 23
8-K
Nemaura Medical Completes 100 Patient Study for sugarBEATÒ 24-hour Wear and Reports Interim Results
11 Sep 23
DEFA14A
Additional proxy soliciting materials
8 Sep 23
DEF 14A
Definitive proxy
8 Sep 23
8-K
Regulation FD Disclosure
17 Aug 23
10-Q
2024 Q1
Quarterly report
14 Aug 23
8-K
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update
14 Aug 23
8-K
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
11 Aug 23
PRE 14A
Preliminary proxy
10 Aug 23
EFFECT
Notice of effectiveness
8 Aug 23
POS AM
Prospectus update (post-effective amendment)
3 Aug 23
10-K/A
2023 FY
Annual report (amended)
17 Jul 23
8-K
Results of Operations and Financial Condition
14 Jul 23
10-K
2023 FY
Annual report
13 Jul 23
NT 10-K
Notice of late annual filing
29 Jun 23
8-K
Nemaura Medical Scales-Up Pilot Expansion of proBEATTM; 56 Corporations in the USA signed up for pilots, in June 2023
27 Jun 23
8-K
Changes in Registrant's Certifying Accountant
31 May 23
424B4
Prospectus supplement with pricing info
15 May 23
EFFECT
Notice of effectiveness
15 May 23
Latest ownership filings
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
4
Arash Ghadar-Ghadr
9 Jan 24
3
Arash Ghadar-Ghadr
9 Jan 24
4
Salim Natha
1 Feb 22
4
Thomas Peter Moore
1 Feb 22
4
Justin James Mclarney
1 Feb 22
4
Timothy Christopher Johnson
1 Feb 22
4
Dewan Fazlul Hoque Chowdhury
1 Feb 22
4
Bashir Timol
1 Feb 22
3
Thomas Peter Moore
10 Nov 21
3
Timothy Christopher Johnson
2 Nov 21
3
Justin James Mclarney
2 Nov 21
4
Bashir Timol
7 Jun 18
4
Sufyan Ismail
7 Jun 18
4
Dewan Fazlul Hoque Chowdhury
7 Jun 18
4
Bashir Timol
5 Jun 18
4
Sufyan Ismail
5 Jun 18
4
Dewan Fazlul Hoque Chowdhury
5 Jun 18
3
Salim Natha
5 Jun 18
3
Iain Anderson
5 Jun 18
SC 13G
Nemaura Medical Inc.
2 Mar 18